Skip to Content

'
Michael E. Rytting, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Rytting graduated from the University of Michigan Medical School, completed an Internal Medicine/Pediatrics residency at the University of Texas Health Science Center-Houston, and completed a fellowship in Pediatric Hematology/Oncology at the University of Texas M.D. Anderson Cancer Center. He is currently an associate professor of pediatrics at the University of Texas M.D. Anderson Cancer Center, and he has a joint appointment in adult leukemia. Dr. Rytting specializes in pediatric leukemia and lymphoma as well as young adult acute leukemia, and his clinical research is predominantly in acute lymphoblastic leukemia in young adults. In addition he works in the pediatrics neuro-oncology section, where his focus is on ependymoma and pontine glioma.  

Education & Training

Degree-Granting Education

1990 University of Michigan, Ann Arbor, MI, MD, Medical Degree
1985 Cornell University, Ithaca, NY, BA, General Biology & Spanish Literature

Board Certifications

2001 American Board of Pediatrics - Diplomate
1998 American Board of Pediatric Hematology/Oncology - Diplomate
1995 American Board of Internal Medicine - Diplomate
1994 American Board of Pediatrics - Diplomate

Selected Publications

Peer-Reviewed Original Research Articles
1. Ren Y, Medeiros LJ, Amin HM, Rytting ME, Jorgensen JL, Chen W. Unusual expression of CD94 on CD8+ TCR-alpha beta T cells in infectious mononucleosis. Ann Diagn Pathol 11:55-60, 2/2007. PMID: 17240309.
2. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'Brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279, 11/2006. PMID: 16882711.
3. Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, Rubnitz JE, Ribeiro RC, Rytting M, Pui CH, Kantarjian H, Jeha S. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer 106(11):2495-502, 6/1/2006. PMID: 16639734.
4. Razzouk B, Estey E, Pounds S, Lensing S, Brandt M, Rubnitz J, Ribeiro R, Rytting ME, Pui C, Kantarjian H, Jeha S. Impact of age on outcome of pediatric acute myeloid leukemia: A report from two institutions. Cancer 106(11):2495-2502, 4/2006.
5. Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Phase II Study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 24(12)(12):1917-1922, 4/2006. PMID: 16622268.
6. Corey S, Elopre M, Weitman S, Rytting ME, Robinson L, Rumelhart S, Goldman F. Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol 27(3):166-168, 2005.
7. Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 44(11):1309-22, 11/2004. PMID: 15496649.
8. Rytting ME. Pediatric myelodysplastic syndromes. Current Hematology Reports 3(3):173-177, 5/2004. PMID: 15087064.
9. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103(3):784-789, 2/2004. PMID: 14551141.
10. Rytting M, Pearson P, Raymond AK, Ayala A, Murray J, Yasko AW, Johnson M, Jaffe N. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res 373:39-50, 4/2000. PMID: 10810461.
11. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha S, Kuttesch JF, Rolston KV. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 86(1):126-34, 7/1999. PMID: 10391572.
12. Ravandi F, Rytting ME, Osmon C, Braud EL, Roach RW, Edwards K, Winn R, Abbruzzese JL, Pazdur R. Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. Anticancer Drugs 10(6):519-524, 7/1999. PMID: 10885898.
13. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol 21(3):212-18, 1999. PMID: 10363854.
14. Mullen CA, Petropoulos D, Rytting M, Jeha S, Zipf T, Roberts WM, Rolston KV. Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia. J Pediatr Hematol Oncol 20(5):516-517, 1998. PMID: 9787333.
15. Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am 10(2):365-376, 1996. PMID: 8707760.

Last updated: 8/11/2009